摘要
扼要介绍重组蛋白多肽类药物的临床药代动力学研究的内容、方法和特点。综述了重组内皮抑制素、重组糖基化血小板生成素、改构肿瘤坏死因子、重组糖基化尿激酶原、人源化单抗trastuzumab和重组人肿瘤坏死因子受体临床药代动力学研究的方法学。
The clinical pharmacokinetics on recombinant protein or peptides,including the methodology, contents, and characteristics were introduced in brief.The recombinant endostatin,recombinant glycosylated thrombopoeitin,recombinant modified tumor necrosis factor alpha,recombinant glycosylated prourokinase,humanized monoclonal antibody trastuzumab,and recombinant human tumor necrosis factor receptor were reviewed with respect to their methodology and pharmacokinetic behavior.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2002年第10期750-756,共7页
Chinese Journal of New Drugs
基金
国家自然基金资助重点项目 ( 39930 180 )